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RESEARCH ARTICLE
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Abstract
IL-33 is a tissue-derived cytokine that induces and amplifies eosinophilic inflammation and
has emerged as a promising new drug target for asthma and allergic disease. Common vari-
ants at IL33 and IL1RL1, encoding the IL-33 receptor ST2, associate with eosinophil counts
and asthma. Through whole-genome sequencing and imputation into the Icelandic popula-
tion, we found a rare variant in IL33 (NM_001199640:exon7:c.487-1G>C (rs146597587-C),
allele frequency = 0.65%) that disrupts a canonical splice acceptor site before the last
coding exon. It is also found at low frequency in European populations. rs146597587-C
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associates with lower eosinophil counts (β = -0.21 SD, P = 2.5×10–16, N = 103,104), and
reduced risk of asthma in Europeans (OR = 0.47; 95%CI: 0.32, 0.70, P = 1.8×10–4, N cases
= 6,465, N controls = 302,977). Heterozygotes have about 40% lower total IL33 mRNA
expression than non-carriers and allele-specific analysis based on RNA sequencing and
phased genotypes shows that only 20% of the total expression is from the mutated chromo-
some. In half of those transcripts the mutation causes retention of the last intron, predicted
to result in a premature stop codon that leads to truncation of 66 amino acids. The truncated
IL-33 has normal intracellular localization but neither binds IL-33R/ST2 nor activates ST2-
expressing cells. Together these data demonstrate that rs146597587-C is a loss of function
mutation and support the hypothesis that IL-33 haploinsufficiency protects against asthma.
Author summary
Only a few genes have been found to play a role in asthma. These include the genes IL33
and IL1RL1, and sequence variants in the human genome close to these genes were ini-
tially found to affect the number of eosinophils, cells that play a role in inflammation of
the airways in asthma. Based on this knowledge, we decided to use high resolution
sequencing technology to search for variants in these genes that cause changes in structure
and function of the proteins they encode. We found a rare (0.65%) sequence variant in the
IL33 gene, that causes less production of the IL33 protein and some of the protein formed
lacks the capacity to bind to its receptor on cells and promote inflammation. This rare
mutation causes reduced number of eosinophils in blood and protects against asthma.
These results suggest that drugs that could interfere with the inflammatory activity of the
IL33 protein may be beneficial for treatment of asthma.
Introduction
Asthma is characterized by airflow obstruction, airway hyper-responsiveness and airway
inflammation, that promotes mucus obstruction. The inflammatory cytokine IL-33 is widely
expressed[1, 2] and abundantly in the bronchial epithelium. IL-33 resides in the nucleus due
to chromatin-binding motifs[3] but is released after exposure to e.g. viruses or allergens. IL-33
binds to its receptor ST2[4] (also called IL1RL1, IL-33R) and activates eosinophils and other
immune cells promoting inflammation[5], particularly in the lung[6, 7]. IL-33 also binds to a
soluble isofrom IL1RL1-a/sST2, which is thought to act as a decoy receptor and ameliorates
airway inflammation[8].
Through GWAS, we previously discovered common sequence variants in IL1RL1 and IL33
that associate strongly with blood eosinophil counts and risk of asthma, consistent with the
link between eosinophilic inflammation and asthma [9]. The association between IL1RL1 and
IL33 variants and asthma risk is well established [10] and has been replicated in ethnically
diverse populations[11, 12], and in severe forms of adult asthma[11] and in particular with
early childhood[13] asthma with exacerbations.
The critical role of eosinophilic airway inflammation in asthma[14] together with robust
association of eosinophil counts and asthma with common variants at the IL33 and IL1RL1
loci prompted us to search for novel sequence variants at these loci affecting eosinophil counts
using high-coverage sequencing [15]. The variants were identified through sequencing of
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8,453 Icelanders and imputed into 150,656 chip-typed Icelanders[15]. In light of the role of
eosinophils in pathogenesis of asthma and the previously established association of common
variants at the IL33 and IL1RL1 loci with eosinophil counts and asthma, individual sequence
variants at these loci found to associate significantly with eosinophil counts were further
assessed for their effects on asthma.
Results
We focus on the association of sequence variants in two 800kb regions centered on IL33
(chr9:5.8–6.6Mb(hg38)) and IL1RL1 (chr2:101.9–102.7Mb(hg38)) with eosinophil counts in
103,104 Icelanders[16]. Sequence variants were weighted according to their prior probability
of affecting gene function by applying different thresholds for genome-wide (gw) significance
that depend on the variant class[17].
Stepwise conditional analysis at the IL33 locus revealed two significant uncorrelated (pair-
wise r2<0.02) variants (Fig 1 and S1 Fig, Table 1 and S1 Table). One association is novel:
rs146597587-C a rare variant (allelic frequency (AF) = 0.65%) that is predicted to disrupt a
canonical splice acceptor site at the beginning of the last exon of IL33[18, 19] (NM_001199640:
exon7:c.487-1G>C, βadj = -0.21 SD; Padj = 2.5×10–16) (Table 2). rs146597587-C associates with
lower eosinophil counts and is not correlated with previously reported variants at the IL33
locus (S2 Table). The second variant, rs2095044-T (AF = 24.5%), upstream of IL33, is associ-
ated with increased eosinophil count (βadj = 0.051 SD; Padj = 3.6×10–27) and is highly correlated
with rs2381416 (r2 = 0.94), originally described to associate with eosinophil counts and asthma
[9] (Table 1, S3 and S4 Tables). A potential secondary signal was noted, rs10758750-G (AF =
27.7%), an intronic variant in IL33 (βadj = -0.023 SD; Padj = 5.7×10–7) (Table 1) (passing a sig-
nificance threshold of 2.8×10–6, corresponding to a Bonferroni correction for the number of
variants tested (17,935) at the two loci[20]), uncorrelated (pairwise r2<0.02) to the novel vari-
ant reported here (Fig 1 and S1 Fig, Table 1 and S1 Table) and to the previously reported vari-
ants at the IL33 locus (S2 Table).
Among the two significant variants, the splice acceptor mutation rs146597587-C has the
largest effect. The splice acceptor mutation is present in both Europeans (AF = 0.35%) and
South-Asians (AF = 0.10%) in the Exome Aggregation Consortium (ExAC) database where it
is>10 times more frequent than any other predicted loss-of-function variant in IL33 (S5
Table, URLs). In total we tested six predicted missense, splice region or loss-of-function
variants in IL33 (S6 Table) and only the association with the splice acceptor mutation
rs146597587-C is significant (P>0.2 for the others). None of the twelve variants highly corre-
lated (r2>0.8) with the splice acceptor mutation were coding, making it most likely to be
responsible for the effect (S7 Table). Neither of the two other associating variants, rs2095044
nor rs10758750, were correlated with a coding variant (S4 and S8 Tables).
The IL33 splice acceptor mutation, rs146597587-C was genotyped in 1,370 Dutch samples
and its effect on eosinophil counts was replicated (β = -0.48 SD, P = 0.036, AF = 0.69%)
(Table 2).
Once the eosinophil count association of the splice acceptor variant was established, we
assessed its effect on asthma, based on the prior association of IL33 and with asthma risk and
the role of eosinophils in the pathogenesis of asthma. We assessed the effect of rs146597587-C
on asthma in Iceland[9], The Netherlands[21–23], Germany [24] and Denmark[25, 26],
including Danish children with severe asthma with at least 2 exacerbations leading to hospitali-
zation between 2 and 6 years of age (COPSACexacerbation)[13]. The IL33 splice acceptor muta-
tion protects against asthma (OR = 0.47; 95% CI: 0.32–0.70, P = 1.8×10–4) (Table 2). We did
not observe heterogeneity of the effect in the different sample sets (Phet = 0.24, I2 = 26.8). Thus,
Genetic evidence for key role of IL33 in eosinophil counts and asthma
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Fig 1. Overview of eosinophil counts associations in the region around IL33. (A) shows an 800kb overview centered on
IL33 on chromosome 9 and (B) shows a 100kb overview around the IL33 gene. Black circles show -log10 P as a function of hg38
coordinates for associations with eosinophil counts and red crosses correspond to eosinophil counts associations after adjusting
for the three variants rs2095044, rs146597587 (splice acceptor) and rs10758750 that are indicated by vertical broken lines in (B).
Genes are shown in blue and recombination rates are reported in cM/Mb. (See S1 Fig for intermediate results from stepwise
regression.)
https://doi.org/10.1371/journal.pgen.1006659.g001
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this rare splice acceptor mutation reduces eosinophil counts and protects against asthma,
whereas the minor allele of the common rs2095044-T associates with higher eosinophil counts
and increased risk of asthma (Tables 1 and 2).
Stepwise conditional analysis of the association with eosinophil counts (N = 103,104) at
the IL1RL1 locus revealed two significant variants, an intronic variant, rs13020553-G
Table 1. Association of common sequence variants in IL33 and IL1RL1 with eosinophil counts and asthma in Iceland.
Marker Pos. (hg38) A1 Freq.
A1b [%]
gene
context
Eosinophil counts (N = 103,104) Asthmaa (Naffected = 3,512, Ncontrols =
298,026)
unadjusted adjusted unadjusted adjusted
Βc (95%CI) P βc (95%CI) P ORd (95%
CI)
P ORd (95%
CI)
P
IL33 locus:
rs2095044 chr9:
6,192,796
T 24.5 intergenic 0.051
(0.04,0.06)
1.1×10–26 0.051
(0.04,0.06)
3.6×10–27 1.12
(1.04,1.20)
0.0018 1.10
(1.03,1.18)
0.0048
rs10758750e chr9:
6,230,513
G 27.7 Intronic
(IL33)
-0.016
(-0.03,-0.01)
5.1×10–4 -0.023
(-0.03,-0.01)
5.7×10–7 1.06
(0.98,1.14)
0.12 1.04
(0.97,1.12)
0.27
IL1RL1 locus:
rs13020553 chr2:
102,315,366
G 41.9 intronic
(IL1RL1)
0.048
(0.04,0.06)
3.5×10–31 0.043
(0.03,0.05)
1.6×10–24 1.06
(0.99,1.13)
0.078 1.04
(0.98,1.10)
0.19
rs6719123 chr2:
102,259,080
G 14.2 intergenic -0.048
(-0.06,-0.04)
1.3×10–16 -0.037
(-0.05,-0.03)
7.0×10–10 0.92
(0.85,1.00)
0.049 0.92
(0.85,1.01)
0.083
Association results for each variant is presented with and without adjusting for the other variants at its locus in this table. All the variants were well imputed
(imputation information = 1.00).
a) The asthma sample set includes young adults, 45 years old or younger[9] (Materials and methods).
b) Freq. A1: Allelic frequency for allele A1.
c) β: Effect in SD with respect to allele A1.
d) OR: Odds ratio with respect to allele A1.
e) rs10758750 shows suggestive association with eosinophil counts, passing a significance threshold of 2.8×10–6, corresponding to a Bonferroni correction
for the number of variants tested (17,935) at the two loci[20].
https://doi.org/10.1371/journal.pgen.1006659.t001
Table 2. Associations of the IL33 splice acceptor variant rs146597587[C] with eosinophil counts and asthma in Iceland and abroad.
Eosinophil counts AF β (SD) (95%CI) P N individuals Phet, I2
Iceland 0.65% -0.21 (-0.27, -0.16) 2.5×10–16 103,104
The Netherlands 0.69% -0.48 (-0.93, -0.03) 0.036 1,370
Combined -0.22 (-0.27, -0.17) 5.3×10–17 104,474 0.25, 25.0
Asthma AF OR (95%CI) P N cases N controls
Iceland: 0.65% 0.36 (0.21, 0.61) 1.2×10–4 3,512 298,026
The Netherlands 0.53% 1.08 (0.36, 3.21) 0.89 351 2,830
Germany 0.40% 0.89 (0.14, 5.48) 0.90 284 252
Denmark-1 0.50% 0.72 (0.29, 1.79) 0.48 1,121 1,004
Denmark-2 (COPSAC) 0.45% 0.24 (0.06, 0.94) 0.04 1,197 865
Combined 0.47 (0.32, 0.70) 1.8×10–4 6,465 302,977 0.24, 26.8
Allele frequency (AF) of rs146597587[C], the effect (β (SD)) on eosinophil counts and odds ratio (OR) for asthma and the corresponding P-values are
provided, in addition to the number of individuals, or cases and controls tested. All the asthma sample sets include children and/or young adults: Iceland 45
years age or younger[9], The Netherlands younger than 45 years of age[23, 42], Germany 5–18 years of age[24], Denmark-1 14 to 44 years of age[25, 26]
and Denmark-2 (COPSAC) children with severe asthma with at least 2 exacerbations leading to hospitalization between 2 and 6 years of age[13] (Materials
and methods).
https://doi.org/10.1371/journal.pgen.1006659.t002
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(MAF = 41.9%), increasing eosinophil counts (β = 0.043, Padj = 1.6×10–24) and an intergenic
variant, rs6719123-G (MAF = 14.2%), decreasing eosinophil counts (β = -0.037, Padj =
7.0×10–10) (Table 1 and S9 Table); no other variant at the locus remained significant after
adjusting for these two (Fig 2 and S10 Table). rs13020553 is highly correlated with rs1420101
(r2 = 0.96, D’ = 1.00), originally reported to associate with eosinophil counts and asthma[9]
(S3 and S10 Tables). Despite the high correlation, rs1420101-T (that is on the background
of rs13020553-G) does not fully explain the eosinophil association of rs13020553, whereas
rs13020553 fully explains the eosinophil association for rs1420101 (S10 Table). Together
rs13020553 and rs6719123 explain all the reported effects on eosinophil counts and asthma at
the locus (S3 Table); however, the reported variants do not fully explain the signal captured by
rs13020553 and rs6719123 (S11 Table).
We found and tested 75 coding or splice region variants at the IL1RL1 locus. Among those
not in IL1RL1, only one was significant (P>0.001 for all other coding variants not in IL1RL1),
rs1420098-C, a splice region variant in IL18R1 (MAF = 42.5%, P = 3.8×10–24, β = 0.042). The
eosinophil counts association of rs1420098 was fully accounted for by rs13020553 (r2 = 0.81,
Padj = 0.53), whereas the association of rs13020553 could not be accounted for by rs1420098
Fig 2. Conditional analysis for eosinophil counts associations in the region around IL1RL1. Plot shows an 800kb overview around the IL1RL1 gene
on chromosome 2. Black circles (o) show-log10 P as a function of hg38 coordinates for unadjusted associations with eosinophil counts; red crosses (+)
correspond to eosinophil counts associations after adjusting for the variant rs13020553; blue ‘x’ symbols correspond to eosinophil counts associations after
adjusting for both rs13020553 and rs6719123. The position of the two variants rs13020553 and rs6719123 are indicated by vertical broken lines. Genes are
shown in blue and recombination rates are reported in cM/Mb.
https://doi.org/10.1371/journal.pgen.1006659.g002
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(Padj = 1.2×10–8, βadj = 0.054). We observed two significant coding signals in IL1RL1 among
the sixteen detected and tested (14 missense, one splice region variant and one frameshift vari-
ant) (S12 Table). Both coding signals were previously reported to associate with concentration
of ST2 in soluble form (sST2)[27]. The first, represented by rs10192157-T (MAF = 39.0%,
P = 4.2×10–20; HGVSp: NP_057316.3:p.Thr549Ile), corresponds to five perfectly correlated
missense variants (r2 = 1.00, D’ = 1.00 for all pairs) moderately correlated with rs13020553
(r2 = 0.35); the second rs1041973-A (MAF = 17.7%, P = 3.5×10–9, HGVSp: NP_057316.3:p.
Ala78Glu) is correlated with rs6719123 (r2 = 0.68) (S13 Table). These two eosinophil counts
associations are fully accounted for by rs13020553 and rs6719123 (S14 Table). We conclude
that the eosinophil counts signals corresponding to rs13020553 and rs6719123 (correlated var-
iants: S15 and S16 Tables) could not be explained by the observed coding variants or reported
variants at the locus. Our results are in agreement with the notion that variants at this locus
influence eosinophil counts by affecting IL1RL1; and IL-33 is known to mediate its biological
effects through ST2/IL1RL1[4].
The splice acceptor mutation in IL33 changes AG to AC at the 3’ splice junction between
the last two exons and is thus predicted to disrupt splicing between them [18, 19]. IL33 is pri-
marily expressed by stromal cells and is expressed at a relatively low level in hematopoetic tis-
sues. Of the two tissues with mRNA sequencing data available to us IL33 is essentially absent
from whole blood but is expressed in subcutaneous adipose tissue[1] (median RPKM of 12.9
in 350 samples), according to the GTExV6 database[2]. We therefore analyzed the effect of the
splice acceptor mutation on the IL33 transcript quantity and processing using the adipose tis-
sue mRNA sequencing (N = 675) dataset (Materials and methods, and Fig 3). Heterozygote
carriers (N = 10) of the splice acceptor mutation showed about 40% lower total IL33 expression
than non-carriers (P = 6.8×10–6) (Fig 3). Comparable results were obtained by accessing total
IL-33 expression with microarray (S2 Fig). Allele-specific analysis of the RNA sequencing
data shows that only 20% of total IL33 transcripts are from the mutated chromosomes
(P = 1.3×10–4) indicating that a large fraction of mRNA originating from the mutated chromo-
somes is likely eliminated through nonsense-mediated decay (NMD)[28]. Analysis of read
coverage in the RNA sequencing data, shows retention of the last intron of IL33 in about half
of the RNA generated from the mutated chromosome (~11% of total RNA) in heterozygotes
compared to 0.6% of that in non-carriers (P = 5.6×10–8). Taken together these data demon-
strate that the splice acceptor mutation leads both to elimination of the mutated transcripts
and a retention of the last intron, introducing a premature stop codon in about half of the
remaining mutated transcripts.
The IL-33 protein generated from the intronic retention transcripts is predicted to lack the
last 66 amino acids (out of 270). IL-33 folds as a 12-stranded “β-barrel” structure, prototypical
for the IL-1 family. Elimination of the last 66 amino acids removes 5 of the 12 core β-strands
and is predicted to disrupt the tertiary structure of the protein. To determine whether IL-33
lacking these residues is functional we expressed recombinant IL-33 lacking the last exon (ter-
mination at residue 204, Fig 4). IL-331–204 was detectable in transfected mammalian cellular
lysates as a 27kD protein, compared to the 35 kD wild type IL-331–270 (S3 Fig). IL-331–204 was
in the nucleus in a manner indistinguishable from IL-331–270 (Fig 4), indicating that the trun-
cation does not disrupt nuclear trafficking.
Computational modeling [29] indicates that truncated IL-33 lacks core structural folds
and key surface residues predicted to contribute to receptor binding (Fig 4A). To determine
whether the truncated form binds ST2 we generated IL-3395–270 (wild type) and IL-3395–204
(truncated mutant) recombinant proteins. The N-terminus starting residue at amino acid
position 95 was chosen based on natural processing of IL-33 before receptor binding[30]
(S4 Fig).
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Using surface plasmon resonance we found that IL-3395–270 bound rapidly to IL-33R/ST2
(Fig 4), consistent with high affinity binding to IL-33R that we previously reported[31],
whereas IL-3395–204 showed no interaction signal, indicating a complete lack of receptor bind-
ing. Furthermore, IL-3395–270 induced a concentration- and IL-33R-dependent CCL1 release
Fig 3. RNA analysis of IL33 mRNA expression and carrier status of the splice acceptor variant rs146597587. (A) Gene structure of IL33 and location
of rs146597587 SNP that changes a canonical splice acceptor site from AG to AC. The mutation lies at the junction of coding exons 6 and 7. Exon 7 begins
LHKCE and encodes a significant portion of the cytokine domain. Also, indicated is the location of an elastase cleavage site at amino acid 95 that releases the
cytokine domain from the N terminus prodomain and leads to a more active cytokine. (B) Expression in FPKM of IL33 in adipose tissue for rs146597587 non-
carriers (GG, N = 744) and carriers (GC, N = 6) based on RNA-Seq data; P(Wilcox) = 0.0015, median non-carriers: 34.1, carriers: 21.1 (i.e. heterozygotes
have 38% lower expression than non-carriers). (C) Ratio of RNA-Seq read coverage in last intron of IL33 versus its last exon (splice acceptor resides at this
intron-exon boundary) for rs146597587 non-carriers (GG, N = 738) and carriers (GC, N = 9); P(Wilcox) = 2.5×10–7, mean non-carriers: 0.67%, carriers: 9.0%.
(D) Proportion of RNA-Seq read with ALT allele for the synonymous variant rs10975519 (MAF = 29%) for rs146597587 non-carriers (GG, N = 309) and
carriers (GC, N = 5); a chromosome carrying rs146597587-C carries the ALT allele of rs10975519; P(Wilcox) = 1.4×10–4, mean non-carriers: 0.48, non-
carriers: 0.20.
https://doi.org/10.1371/journal.pgen.1006659.g003
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in human mast cell line expressing IL-33R (Fig 4C and S5 Fig), whereas IL-3395–204 did not at
any concentration tested, consistent with a complete loss of cytokine activity. The mutant IL-
33 was also inactive compared to wild type inducing IFN-γ release from human CD4+ T cells
(Fig 5).
In il33 knock-out mice, 30% reduced fertility by has been reported[32]. Nine imputed
rs146597587-C homozygotes were found in the Icelandic data and they neither show reduced
life expectancy nor reduced fertility (S16 Table), indicating that a predicted very low level of
IL-33 is compatible with long life and healthy reproduction. Moreover, rs146597587-C homo-
zygosity (recessive model) does not confer risk of any other disease that was tested in the Ice-
landic data[15, 33], indicating that IL-33 is largely dispensable. Two homozygotes of the splice
acceptor mutation are reported in ExAC (S5 Table, URLs). An association of il33 polymor-
phism with eosinophil numbers in rats has been reported[34] and we found that deletion of
il33 leads to significant reduction in blood eosinophils in unchallenged mice (P = 0.014 males,
P = 0.00010 females) (Fig 6), mimicking our human observations.
Discussion
Resequencing of 100 genes implicated in asthma only revealed a few coding variants associat-
ing with asthma[35]. Since eosinophils are known to play a key role in inflammation of the
airway in asthma[12] we used high-coverage sequencing [13] to search for novel sequence var-
iants affecting eosinophil counts at the well established asthma loci, the IL33 and IL1RL1 loci,
Fig 4. (A) Computational model of the IL-33 cytokine domain bound to its receptor. Shown in pink are amino acids 205–270, which are derived from exon 7
and absent in the rs146597587-C-associated truncated form of IL-33. Besides contributing to overall structure, this part of IL-33 also contributes to receptor
interaction. (B) Binding profile from Biacore surface plasmon resonance measurement of IL-33 binding to IL-33R. Recombinant IL-33R encompassing the
extracellular domain was immobilized on the chip surface and then recombinant IL-33 was allowed to flow over the chip (beginning at time 0). Productive
receptor binding is indicated by a prolonged increase in resonance following cytokine addition. Wild type IL-33 (95–270) bound receptor, but the mutant IL-33
(95–204) did not. (C) Biological response to IL-33. LAD2 human mast cells were treated with the indicated concentrations of either wild type IL-33 (95–207) or
mutant IL-33 (95–204) and concentration of CCL1 released into the culture medium was measured by ELISA. (D) Schemata of constructs made to evaluate
expression of full-length IL-33 proteins in mammalian cells or, for expression and purification of cytokine domain-only proteins in E. coli. (E)
Immunofluorescent staining indicating equivalent nuclear localization of full-length wild type IL-33 (1–270) and the rs146597587[C]-associated form of IL-33
(1–204) in transfected HEK293 human epithelial cells.
https://doi.org/10.1371/journal.pgen.1006659.g004
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and tested their effects on asthma. Our results indicate that variants at the IL1RL1 locus affect
eosinophil counts and the risk of asthma most likely by affecting IL1RL1 itself. IL-33 is known
to mediate its biological effects through ST2/IL1RL1[4] and sensitized mice with il1rl1
(ST2-/-) knocked out show less eosinophil numbers in bronchoalveolar lavage fluid upon aller-
gen exposure than wild-type mice, reduced levels of Th2 cytokines and chemoattractants in
the lungs, and reduced goblet cell hyperplasia around the peripheral airways in murine models
of allergy and asthma[36, 37].
We report a rare variant, rs146597587, in IL33 representing a loss-of-function mutation in
this known asthma gene. This splice acceptor mutation associates with lower eosinophil counts
and protection against asthma, with the largest protective effect from severe asthma with fre-
quent exacerbations in young Danish children (OR = 0.24, Table 2). This is in agreement with
increasing risk conferred by the common IL33 variant rs2381416 with increasing severity of
asthma in these children, with OR from 1.27 to 1.69 for severity groups 1 to 4 (S17 Table). The
splice acceptor mutation caused reduced expression of IL33 transcripts, likely due to NMD,
and production of truncated IL-33 that lacks the cytokine function due to lack of binding to
IL-33R/ST2 resulting in abrogation of IL-33R-dependent release of CCL1 from mast cells and
Fig 5. Activity of IL-33 variants in human CD4 T cell bioassay. Purified human blood CD4 T cells were incubated in the presence or absence of IL-
2 and IL-12 for 72 hours and IFN-γwas measured in the cell-free supernatants (as described in online methods). Both IL-33 (95–270) (Amgen) and IL-
33(112–270) (R&D Systems) were used as positive controls and two independent lots of IL-33(95–204) were tested. (A) IL-33, IL-2 and IL-12
dependence of assay with IL-33 at 10ng/mL; (B) Dose titration of IL-33 variants (in the presence of 10 ng/mL IL-2 and 10 ng/mL IL-12). (C) ST2
dependence of response. IL-33 variants (10 ng/mL plus IL-2 and IL-12) were tested in the presence of 25 ug/mL human IgG2 control antibody or IgG2
anti-human ST2 blocking antibody.
https://doi.org/10.1371/journal.pgen.1006659.g005
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IFN-γ release from human CD4+ T cells. We therefore infer that asthma risk is mediated
through IL-33. Accordingly, common variants in IL1RL1 that associate with increased asthma
risk associate with reduced expression of soluble ST2[38, 39], with the predicted effect being
increased IL-33 activity, due to reduced level of this decoy receptor. Thus, human genetics sup-
port the rationale for therapeutically inhibiting the IL-33-ST2 pathway in an attempt at con-
taining asthma.
Materials and methods
Ethics statement
The Icelandic study was approved by the National Bioethics Committee (VSN_14–099) and
the Data Protection Authority (no. PV_2014060841/ÞS) in Iceland. All participating subjects
who donated blood provided informed consent. Personal identities of the participants and bio-
logical samples were encrypted by a third-party system approved and monitored by the Icelan-
dic Data Protection Authority.
The Denmark-1 study was approved by the local ethics committee of Copenhagen, Denmark
(Approval no. KF01-400/98 and KF01-074/01). All participants signed informed consent.
The COPSAC study research protocol was approved by The Danish National Ethical Com-
mittee on Health Research (KF 01-289/96, H-B-2008-093, H-16039498 and H-B-2998-103)
and is in accordance with the ethical scientific principles of the Helsinki Declaration II. All
parents in the cohorts signed informed consent.
The German study was approved by the Ethical Commission of the University of Freiburg
(Approval no. 96/05). All participants signed informed consent.
The Dutch European ancestry asthma study was approved by the Medical Ethics Commit-
tee of the University Hospital Groningen (Approvals no. MEC 90/09/178, MEC 96/04/077,
MEC 97/10/184). All participants signed informed consent. The Dutch Vlagtwedde/Vlaar-
dingen study protocol was approved by the local university medical hospital ethics committee,
University of Groningen, University Medical Center Groningen, The Netherlands and all
Fig 6. Blood eosinophil counts from wild type and il33-deficient mice. Blood were collected from male
and female 10–12 week old mice and eosinophils were enumerated as described in the online methods. The
horizontal bars indicate means within groups. Significance calculated using the unpaired T test, p = 0.014
males, p = 0.0001 females.
https://doi.org/10.1371/journal.pgen.1006659.g006
Genetic evidence for key role of IL33 in eosinophil counts and asthma
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006659 March 8, 2017 11 / 24
participants gave their written informed consent. In 1984, the Committee on Human Subjects
in Research of the University of Groningen reviewed the study and affirmed the safety of the
protocol and study design.
The mouse experiments were performed at Amgen Inc. All animal use procedures were in
accordance with Amgen animal use and care guidelines and approved by IACUC.
Study sample sets for eosinophil count and asthma
Iceland. We obtained eosinophil counts from three of the largest laboratories in Iceland
(measurements performed between the years 1993 and 2015). The median eosinophil counts
were 200/μl (lower and upper quartiles: 100/μl and 300/μl). The circulating eosinophil counts
were standardized to a standard normal distribution using quantile-quantile standardization
and then adjusted for sex, year of birth and age at measurement, as previously described[9,
40]. A total of 103,104 individuals with eosinophil counts were included in the study, where
82,642 were chip-typed and directly imputed; the remaining 20,462 were first and second
degree relatives of chip-typed individuals and had their genotypes inferred based on genealogy
[16].
Icelandic asthma patients over 18 years of age who attended an asthma clinic or emergency
room at the National University Hospital of Iceland or the Icelandic Medical Center (Laekna-
setrid) during the years 1977 to 2014 were recruited[9]. Asthma diagnosis was based on a com-
bination of physician’s diagnosis, a positive reply to the question: „Has a doctor confirmed
your asthma diagnosis?“, questionnaires pertaining to asthma symptoms and ICD diagnosis
when receiving emergency care[9, 40]. Atopy status (defined by at least one positive response
to allergens) determined by skin prick testing was available for part of the cohort. A total of
3,512 (1,842 chip-typed) asthma cases 45 years old or younger were used in the study (18.5%
with known age of onset 18 years of age or younger) [9, 40] and 298,026 (134,762 chip-typed)
controls. Icelandic controls were participants from various deCODE genetics programs with-
out known asthma.
The study was approved by the National Bioethics Committee (VSN_14–099) and the Data
Protection Authority (no. PV_2014060841/ÞS) in Iceland. All participating subjects who
donated blood provided informed consent. Personal identities of the participants and biologi-
cal samples were encrypted by a third-party system approved and monitored by the Icelandic
Data Protection Authority.
Denmark 1. Asthma subjects and controls from three studies at the Copenhagen Research
Unit, aged 14 to 44 years and resided in Copenhagen, Denmark, were used in the analysis[25,
26]. The asthma patients had doctor diagnosed asthma by a respiratory specialist and had
undergone a physical examination and spirometry. Danish control subjects were recruited
through the Danish Blood Donor Corps in the Copenhagen area.
Denmark 2 (COPSAC). Cases were from the COPSACexacerbation cohort. Children with
repeated acute hospitalizations (cases) were identified in the Danish National Patient Register
covering all diagnoses of discharges from Danish hospitals[41]. Information on birth-related
events was obtained from the national birth register. Inclusion criteria were at least two acute
hospitalizations for asthma (ICD-8-code 493, ICD-10 codes J45-46) from 2 to 6 years of age, as
previously described[13]. Duration of hospitalization had to be more than 1 day, and two hos-
pitalizations had to be separated by at least 6 months. Exclusion criteria were side diagnosis
during hospitalization, registered chronic diagnosis considered to affect risk of hospitalization
for asthma, low birth weight (<2.5 kg) or gestational age of under 36 weeks at birth. Control
subjects were children without asthma exacerbations in the COPSAC2000 and COPSAC2010
birth cohorts. Study participants gave informed consent for use of their biological samples for
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genetic studies. The research protocol was approved by The Danish National Ethical Commit-
tee on Health Research and is in accordance with the ethical scientific principles of the Hel-
sinki Declaration II.
Germany. The German case-control population consisted of children (aged 5–18 years)
with suspected asthma recruited from the southwestern part of Germany between July 2000
and January 2005[24]. The probands were characterized at the Centre of Pediatrics and Ado-
lescent Medicine, Freiburg, Germany. The diagnosis of asthma was based on a history of
respiratory symptoms, the use of anti-asthmatic medication and the presence of bronchial
hyperresponsiveness (defined as a fall of at least 15% in baseline FEV1 after either inhalation
of8 mg/ml histamine or6 minutes of exercise provocation). Participants were asked in
advance to discontinue any asthma or allergy medication before the clinical testing. Atopy sta-
tus was determined by skin prick tests to 17 common allergens. Measurement of total serum
IgE was carried out by using an enzyme allergosorbent test (Phadezym; Pharmacia, Uppsala,
Sweden). The control sample consisted of subjects (aged 19–40 years) randomly chosen from
the same area in the southwestern part of Germany and children recruited from clinics at the
Centre of Pediatrics and Adolescent Medicine, Freiburg, Germany. No medical history was
taken, and no medical testing was performed on the adult controls whereas the pediatric
controls had no previous history of asthma, recurrent wheezing, atopic dermatitis or atopy.
Approval was granted by the Ethical Commission of the University of Freiburg. A statement
of informed consent was signed by all participants or signed by their parents in the case of
children.
The Netherlands. The Dutch cases have been previously described[21–23]. Briefly asthma
patients of European ancestry were initially studied between 1962 and 1975. At the time of
recruitment and initial testing, all patients had asthma symptoms, were hyperresponsive to his-
tamine (PC20 histamine <32 mg/ml), and were younger than 45 years of age. Between 1990
and 1999, patients were invited for follow-up tests: including pulmonary function, bronchial
responsiveness to histamine, and total and specific serum IgE and skin tests to 16 common
aero allergens [22, 23]. Participants were asked in advance to discontinue asthma or allergy
medication, therapy with oral corticosteroids was however continued.
A second independent Dutch asthmatic population was ascertained between 1998 and
2001, consisting of probands with asthma, ascertained through local hospitals and media
appeals. Controls were derived from Vlagtwedde/Vlaardingen cohort study, a population-
based cohort of adult subjects of European ancestry in the Netherlands, recruited from 1965
with a follow-up of over 25 years. Surveys were performed every 3 years, in which information
was collected on respiratory symptoms, smoking status, FEV1, and allergy skin tests [42].
Whole-genome sequencing and imputation
Genotyping of all Icelandic samples was carried out at deCODE genetics in Reykjavik, Iceland,
using methods recently described[15]. In brief, whole-genome sequencing was performed for
8,453 Icelanders who were recruited as part of various genetic programs at deCODE genetics,
to an average depth of at least 10× (median 32×) using Illumina technology. The sequencing
was performed using the following three different library preparation methods and sequencing
instruments from Illumina: (i) standard TruSeq DNA library preparation method; Illumina
GAIIx and/or HiSeq 2000 sequencers; (ii) TruSeq DNA PCR-free library preparation method;
Illumina HiSeq 2500 sequencers; and (iii) TruSeq Nano DNA library preparation method; Illu-
mina HiSeq X sequencers (S1 Method).
SNPs and indels identified in the whole-genome sequencing data were identified using the
Genome Analysis Toolkit HaplotypeCaller (GATK version 3.3.0)[43] and imputed into
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150,656 Icelanders who had been genotyped with various Illumina SNP chips and their geno-
types phased using long-range phasing chip-genotyped individuals using long-range phasing
[44]. In addition, using the Icelandic genealogical database, genotype probabilities were calcu-
lated for first- and second-degree relatives of chip-genotyped individuals[15]. The effects of
sequence variants on protein-coding RefSeq genes[18] were annotated using the Variant Effect
Predictor (VEP) version 80[19].
Genotyping of single variants
Single SNP genotyping in the replication sample sets was carried out by deCODE Genetics in
Reykjavik, Iceland, applying the Centaurus (Nanogen) platform[45] except that genotyping
single SNPs in the Danish cohort of children with severe asthma was carried out at the AROS
Applied Biotechnology AS center (http://arosab.com/services/microarrays/genotyping/), in
Aarhus, Denmark, applying the Illumina Infinium HumanOmniExpressExome Bead chip
platform and genome studio software[46].
Association testing in Iceland
Generalized linear regression models were used to test for associations between sequence vari-
ants and quantitative traits, assuming an additive genetic model. Let y be the vector of quanti-
tative measurements, and let g be the vector of expected allele counts for the sequence variant
being tested. We assume the quantitative measurements follow a normal distribution with a
mean that depends linearly on the expected allele at the variant and a variance covariance
matrix proportional to the kinship matrix:
y  N ðaþ bg; 2s2FÞ;
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is the kinship matrix as estimated from the Icelandic genealogical database. Logistic regression
was used to test for association between sequence variants and binary traits. Other available
individual characteristics that correlate with disease status were also included in the model as
nuisance variables. These characteristics were: sex, county of birth, current age or age at death
(first- and second-order terms included), blood sample availability for the individual and an
indicator function for the overlap of the lifetime of the individual with the timespan of pheno-
type collection. Testing was performed using the likelihood ratio statistic. Conditional analysis
was performed by including the sequence variant being conditioned on as a covariate in the
model under the null and the alternative in the generalized linear regression. Sequence variants
were weighted according to their prior probability of affecting gene function by applying dif-
ferent thresholds for genome-wide (gw) significance that depend on the variant class[17].
Association summary statistics are provided in supplementary tables for the IL33 locus (S18
Table) and the IL1RL1 locus (S19 Table).
LD score regression. To account for inflation in test statistics due to cryptic relatedness
and stratification, we applied the method of LD score regression[47]. With a set of 1.1M vari-
ant we regressed the χ2 statistics from GWAS scans against LD score and used the intercept as
a correction factor. The LD scores were downloaded from an LD score database (see URLs).
The correction factors were 1.2844 for the eosinophil counts, and 1.1120 for asthma.
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Gene expression microarrays
Samples of RNA from human peripheral blood and adipose tissue were hybridized to Agilent
Technologies Human 25K microarrays as described previously[48] and the effect of SNPs on
the IL33 expression in adipocytes evaluated. We quantified expression changes between two
samples as the mean logarithm (log10) expression ratio (MLR) compared to a reference pool
RNA sample. In comparing expression levels between groups of individuals with different
genotypes, we denoted the expression level for each genotype as 10 (average MLR), where the
MLR is averaged over individuals with the particular genotype. We determined s.e.m. and sig-
nificance by regressing the MLR values against the number of risk alleles carried. We took into
account the effects of age, gender and differential cell type count in blood as explanatory vari-
ables in the regression.
RNA sequencing
The effect of on the IL33 expression in adipocytes was evaluated by RNA sequencing as previ-
ously described[20].
Preparation of Poly-A cDNA sequencing libraries. The quality and quantity of isolated
total RNA samples was assessed using the Total RNA 6000 Nano chip for the Agilent 2100
Bioanalyzer. cDNA libraries derived from Poly-A mRNA were generated using Illumina‘s Tru-
Seq RNA Sample Prep Kit. Briefly, Poly-A mRNA was isolated from total RNA samples (1–
4 μg input) using hybridizaton to Poly-T beads. The Poly-A mRNA was fragmented at 94˚C,
and first-strand cDNA was prepared using random hexamers and the SuperScript II reverse
transcriptase (Invitrogen). Following second-strand cDNA synthesis, end repair, addition of a
single A base, adaptor ligation, AMPure bead purification, and PCR amplification, the result-
ing cDNA was measured on a Bioanalyzer using the DNA 1000 Lab Chip.
Sequencing. Samples were clustered on to flowcells using Illumina‘s cBot and the TruSeq
PE cluster kits v2, respectively. Paired-end sequencing was performed with either GAIIx
instruments using the TruSeq SBS kits v5 from Illumina or HiSeq 2000 instruments using Tru-
Seq v3 flowcells/SBS kits; read lengths were 2x76, 2x101 or 2x125 cycles.
Read alignment. RNA sequencing reads were aligned to Homo sapiens Build 38 with
TopHat[49] version 2.0.12 with a supplied set of known transcripts in GTF format (RefSeq
hg38; Homo sapiens, NCBI, build 38). TopHat was configured such that it attempts first to
align reads to the provided transcriptome then, for reads that do not map fully to the transcrip-
tome, it attempts to map them onto the genome. Read mapping statistics used for read count
normalization were calculated using the CollectRnaSeqMetrics tool in Picard version 1.79
(http://broadinstitute.github.io/picard/command-line-overview.html#CollectRnaSeqMetrics).
After the read alignment step by TopHat, gene expression estimation in FPKM values (Frag-
ments Per Kilobase of transcript per Million mapped reads) was done using Cufflinks[49, 50]
version 2.2.1 for the same set of transcripts used in the read alignment by TopHat.
Mammalian expression
IL-33 variant-expressing vectors as shown in Fig 4D were transfected into HEK293–EBNA1
cells (obtained from National Research Council of Canada) using the protocols described else-
where[51]. At 24 hours post transfection, cells were either seeded onto polylysine-coated glass
coverslips and cultured for 24 hours for imaging, or fed with Difco yeastolate cell culture sup-
plement (BD Biosciences). Cell culture media were collected and whole cell lysates were pre-
pared 2, 4, and 7 days post transfection.
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Cell imaging
At 48 hrs post transfection, cells were fixed with 4% paraformaldehyde in 0.1 M sodium
phosphate, pH 7.2, for 30 minutes at room temperature. After a wash in PBS containing 0.1
M glycine, the fixed cells were incubated with permeabilization buffer (PBS containing 0.4%
saponin, 1% BSA, 5% fish gelatin) for 15 minutes, followed by incubation with primary anti-
body in permeabilization buffer for 60 min. Primary antibodies included anti-IL33 mature
domain (R&D Systems), anti-FLAG (clone M2, Amgen), anti-GAPDH (clone 6C5, Amgen),
anti-gianin (Covance) and anti-GM130 (BD Transduction Lab). After 3 washes in permeabi-
lization buffer, the cells were incubated with Alexa Fluor 488- or 594-conjugated secondary
antibody in permeabilization buffer for 60 minutes. Slides were analyzed using a Nikon
Eclipse 80i microscope using a 100× or 60× CFI Plan Apo oil objective lens. Images were
acquired using a Cool SNAP HQ2 digital camera (Photometrics) and Nikon Elements imag-
ing software.
Western blotting
Harvested cell culture media and processed cell pellets were heated for 5 min at 90˚C in lith-
ium dodecyl sulfate sample buffer (Life Technologies) containing 5% (v/v) beta-mercaptoetha-
nol. NuPAGE 4–12% Bis–Tris gradient gel and the accompanying running buffer system
(both from Life Technologies) were used to perform SDS-PAGE. Resolved proteins were elec-
trotransferred to a nitrocellulose membrane, blocked with fluorescent Western blocking buffer
(Rockland), and probed with primary antibodies (described above). After 3–4 washes in PBS
containing 0.05% (v/v) Tween-20, the nitrocellulose membranes were incubated with Alexa-
Fluor 680- conjugated secondary antibodies (Life Technologies), followed by 2–3 additional
washing steps in PBS containing 0.05% (v/v) Tween-20. The fluorescent Western images were
acquired by using an Odyssey infrared imaging system from LI-COR Biosciences.
E. coli expression and purification
IL-33 was cloned into the pET24a expression plasmid in frame with an amino terminus poly-
His tag and thrombin cleavage site such that thrombin cleavage would release IL-33 proteins
corresponding to residues 95–270 (wild type) or 95–204 (mutant).
For IL-3395–270, following E. coli culture, cell pellets were lysed and the supernatants were
collected and purified on a nickel HisTrap column (GE Healthcare Life Sciences). The material
was eluted from the column using an imidazole gradient. Appropriate fractions were pooled
and further purified by preparative size exclusion chromatography (SEC) using a Superdex 75
column (GE Healthcare Life Sciences) with PBS, pH 7.2, 1 mM DTT as the running buffer.
Recovered material was cleaved using the Thrombin CleanCleave Kit (Sigma) with a 1 hour
incubation at 4˚C. Preparative SEC was used to remove the free His tag and any aggregated
material, followed by an additional SEC step to further reduce endotoxin contamination. IL-
3395–270 was formulated in PBS, pH 7.2, 1 mM DTT, 1 mM EDTA and filtered through a
0.2 μm filter. Endotoxin was undetectable.
IL-3395–204 was not recoverable from the cell pellet supernatant due to low expression in the
soluble fraction. Instead, inclusion bodies were solubilized 1/10 (w/v) with 8 M guanidine, 50
mM Tris, 8mM DTT, pH 9.0 for 1 hour. This was followed by dilution 1/25 (v/v) with PBS
buffer, pH 7.6 and the material was concentrated and loaded onto a Superdex 75 column using
PBS, pH 7.2 as the running buffer. The huIL-33 peak was then buffer-exchanged into 1X
thrombin cleavage buffer (50 mM Tris-HCl, pH 8.0, 100 mM CaCl2) and concentrated to 1
mg/mL. 0.1 mL of thrombin agarose resin (Sigma) was added to 1 mg of huIL-33 and rotated
at 4˚C for 1 hour. Cleaved huIL-33 was then passed over a HisTrap column to capture free
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cleaved His tag. The flow-through material was further purified using preparative SEC, as for
IL-3395–270, prior to formulation in PBS, pH 7.2, 1 mM EDTA. Fractions were analyzed by
SDS-PAGE and Coomassie staining (total protein) or Western blot (with anti-IL-33) before
and after thrombin cleavage to confirm cleavage and IL-33 identity (S4 Fig).
Computational modeling
The structure model of the ST2/IL-33 complex was provided by Lingel et al.[29]. The receptor
and ligand are shown with a molecular surface, computed with default parameters in the
Molecular Operating Environment (MOE, Chemical Computing Group Inc., Montreal, QC,
Canada, H3A 2R7, 2011. (n.d.)), with ST2 shown in gold and IL-33 shown in blue, with amino
acids 205–270, which are derived from exon 7, shown in magenta (Fig 4A).
Surface plasmon resonance
All experiments were performed using a Biacore T200 optical biosensor (Biacore AB). HBS-P
buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.05% Surfactant P20) was purchased from
Teknova. The CM5 sensor chip, sodium dodecyl sulphate (SDS) (0.5% w/v), NaOH (50 mM),
coupling reagents (N-ethyl-N’-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC)/
N-hydroxy-succinimide(NHS)), ethanolamine (1.0 M Ethanolamine-HCl, pH 8.5), Acetate 5.0
(10 mM sodium acetate) and Glycine 1.5 (10 mM glycine, pH 1.5) were purchased from GE
Healthcare Life Sciences. The HCl solution (100 mM) was purchased from Bio Rad Labs. The
penta-His antibody (BSA-free) was purchased from 5Prime. All other reagents were prepared
by Amgen.
Biosensor analysis was conducted at 25˚C in HBS-P buffer. The CM5 sensor chip was con-
ditioned with twice with serial injections (30 seconds) of SDS (0.1%), NaOH (10 mM), HCl
(10 mM) and again with SDS (0.1%) at a flow rate of 30 uL/min (first two injections) or 60 ul/
min (last three injections). The penta-His antibody was diluted (200 ug/mL) in water and then
buffer exchanged via desalting spin column (Zeba, 0.5 mL, 40 K) into Acetate 5.0 buffer. This
buffer-exchanged antibody was immobilized to flow cells 1 (3148 RU) and 2 (7554 RU) of the
sensor chip via standard amine coupling (EDC/NHS) and ethanolamine blocking[52]. Human
ST2-Flag-His (8 ug/mL in HBS-P, Amgen) was injected (300s at 10 uL/min) over flow cell 2.
This captured between 600 and 900 RU of antibody. After the capture step, the human E. coli-
derived IL-33 variants (200 nM) were injected (180s, 50 ul/min) over flow cells 1–2 to observe
the association (180 s) of human IL-33 to human ST2. Each flow cell was then flushed with
running buffer to observe the dissociation of human IL-33 (300 s) from the chip surface. Each
sample of IL-33 was tested individually as a single replicate. A blank buffer injection was tested
before the first sample injection and the surface was regenerated (15 ul at 50 uL/min) with 10
mM glycine pH 1.5 and a reloading of ST2 was captured to the chip surface before each sample
injection.
The data was prepared and analyzed with Scrubber 2.0 software (BioLogic Software Pty Ltd,
Campbell, Australia) as follows. The raw data from each experiment was x and y-axis normal-
ized just prior to the injection of IL-33 and then cropped to include the ST2 capture step and
the association/dissociation of IL-33.
Mast cell bioassay
LAD2 human mast cells were seeded into 48-well tissue culture plates at 250,000 cells/375 μL
media (Stem-Pro-34 serum-free media (Life Technologies, Grand Island, NY, USA) supple-
mented with 2 mM L-glutamine, 100 IU/ml penicillin, 50 μg/ml streptomycin (complete SFM)
and 100ng/ml SCF (Peprotech). The following day cells were stimulated with medium only or
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increasing concentrations (10 pg/mL– 100 ng/mL) of wild-type (95–270) or mutant (95–204)
IL-33 for 24 hours at 37˚C. Culture supernatants were then collected followed by removal of
cell debris by centrifugation and stored at -80˚C until ready for use. The concentration CCL1
in the collected supernatants was determined using an R&D Human CCL1 DuoSet ELISA kit
under manufacturer’s specifications.
To demonstrate the ST2-dependence of the assay, stimulations were performed as described
with the addition of a final concentration of 20 ug/mL human IgG2 isotype control (Amgen)
or human anti-huST2 blocking antibody (Amgen) 30 minutes prior to addition of 100 ng/mL
IL-33.
Human CD4 T cell bioassay
Highly purified human CD4+ T cells were seeded at 200,000 cells/well in 96-well round bot-
tom plates. E. coli-produced human IL-33, either beginning at amino acid 95, as described
above, or using IL-33 (112–270) (R&D Systems) was either titrated as a dose-response or
added to a final concentration of 10ng/mL along with human IL-12 and human IL-2, each at
a final concentration of 10ng/mL. For ST2 blocking, anti-huST2 IgG2 or IgG2 control was
added to a final concentration of 25 ug/mL 30 minutes prior to addition of cytokines. Cultures
were incubated for 72hrs at 37˚C in a 5% CO2 incubator. Cell-free supernatants were collected
and IFN-γ was quantitated by ELISA (R&D Systems).
Mouse eosinophil enumeration
Blood was collected from 10–12 week old wild-type and il33-deficient Bl/6 under isoflurane
anesthesia and analyzed on a Siemens Advia 120 hematology analyzer with mouse-specific
software. Blood smears were air-dried and stained with Wright-Giemsa. Automated differen-
tials generated on the Advia 120 were confirmed by slide evaluation for any sample with eosin-
ophil counts greater than 4% or with evidence of platelet clumps on the Advia scatterplots or
on the blood smear.
URLs
Predicted loss-of-function variants in IL33 and their genotype counts in the Exome Aggrega-
tion Consortium (ExAC) database were retrieved from http://exac.broadinstitute.org/gene/
ENSG00000137033, accessed November 24, 2015.
LD Score database (accessed 23 June 2015), ftp://atguftp.mgh.harvard.edu/brendan/1k_
eur_r2_hm3snps_se_weights.RDS
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